Drug Type Therapeutic vaccine, mRNA vaccine |
Synonyms + [1] |
Mechanism 5T4 inhibitors(Trophoblast glycoprotein inhibitors), MAGEC1 antagonists(MAGE family member C1 antagonists), MAGEC2 antagonists(MAGE family member C2 antagonists) + [3] |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
metastatic non-small cell lung cancer | Phase 3 | CH | 01 Apr 2013 | |
metastatic non-small cell lung cancer | Phase 3 | DE | 01 Apr 2013 | |
metastatic non-small cell lung cancer | Phase 3 | AT | 01 Apr 2013 | |
Non-Small Cell Lung Cancer | Phase 2 | - | - | |
Non-Small Cell Lung Cancer | Phase 2 | - | - | |
Non-Small Cell Lung Cancer | Phase 2 | - | - | |
Non-Small Cell Lung Cancer | Preclinical | DE | - |
AACR2024 Manual | Phase 1 | 57 | (yfobacvrhd) = oztifccvrp havmgfckhp (jpqgekgcmt ) View more | Positive | 05 Apr 2024 | ||
(yfobacvrhd) = otrqtadelp havmgfckhp (jpqgekgcmt ) View more | |||||||
Phase 1/2 | 61 | (Arm A: BI 1361849 mRNA Vaccine + Durvalumab) | vfmnealjsc(nfbcoyjbxq) = lnwabnqagw tcfpcjqfhh (cimhybycxr, doanokavvg - emeyaobtgu) View more | - | 27 Sep 2022 | ||
(Arm B: BI 1361849 mRNA Vaccine + Durvalumab + Tremelimumab) | vfmnealjsc(nfbcoyjbxq) = cagpcysrfv tcfpcjqfhh (cimhybycxr, fnhvauigkx - obnhmgkwaa) View more | ||||||
Phase 1 | 26 | local radiation+BI1361849 | (ouugchyjxt) = Three patients had grade 3 BI1361849-related adverse events (fatigue, pyrexia); there was one grade 3 radiation-related event (dysphagia) ynyldyvmbo (ennlfrayov ) View more | Positive | 08 Feb 2019 |